Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Med Mycol ; 58(8): 1120-1125, 2020 Nov 10.
Article in English | MEDLINE | ID: mdl-32396166

ABSTRACT

Pythium insidiosum is an oomycete that affects mammals, especially humans and horses, causing a difficult-to-treat disease. Typically, surgical interventions associated with antimicrobial therapy, immunotherapy, or both are the preferred treatment choices. PitiumVac® is a therapeutic vaccine prepared from the mycelial mass of P. insidiosum and is used to treat Brazilian equine pythiosis. To better understand how PitiumVac® works, we analyzed the composition of PitiumVac® and the immune response triggered by this immunotherapy in mice. We performed an enzymatic quantification that showed a total glucan content of 21.05% ± 0.94 (α-glucan, 6.37% ± 0.77 and (1,3)(1,6)-ß-glucan, 14.68% ± 0.60) and mannose content of 1.39% ± 0.26; the protein content was 0.52 mg ml-1 ± 0.07 mg ml-1. Healthy Swiss mice (n = 3) were subcutaneously preimmunized with one, two, or three shots of PitiumVac®, and immunization promoted a relevant Th1 and Th17 responses compared to nonimmunization of mice. The highest cytokine levels were observed after the third immunization, principally for IFN-γ, IL-17A, IL-6, and IL-10 levels. Results of infected untreated (Pythiosis) and infected treated (Pythiosis + PVAC) mice (n = 3) showed that PitiumVac® reinforces the Th1/Th17 response displayed by untreated mice. The (1,3)(1,6)-ß-glucan content can be, at least in part, related to this Th1/Th17 response.


Subject(s)
Immunotherapy , Pythiosis/therapy , Pythium/immunology , Th1 Cells/immunology , Th17 Cells/immunology , Animals , Cytokines/immunology , Glucans/analysis , Glucans/immunology , Immunization , Mice , Mycelium/chemistry , Mycelium/immunology , Pythiosis/immunology , Vaccines/administration & dosage , Vaccines/chemistry , Vaccines/immunology
2.
Med Mycol ; 57(3): 324-327, 2019 Apr 01.
Article in English | MEDLINE | ID: mdl-29924372

ABSTRACT

The yeast Malassezia pachydermatis is a common commensal and occasional opportunistic pathogen of theskin microbiota of animals and humans. In this study, the susceptibility of M. pachydermatis isolates to fluconazole (FLC), itraconazole (ITZ), ketoconazole (KTZ), clotrimazole (CLZ), and miconazole (MCZ) alone and in combination with terbinafine (TRB), nystatin (NYS), and caspofungin (CSP) was evaluated in vitro based on the M27-A3 technique and the checkerboard microdilution method using Sabouraud dextrose broth with 1% tween 80 (SDB). Based on the mean FICI values, the main synergies observed were combinations of ITZ+CSP and CLZ+CSP (55.17%). The most significant combinations deserve in vivo evaluations because might provide effective alternative treatments against M. pachydermatis due to their synergistic interactions.


Subject(s)
Antifungal Agents/pharmacology , Malassezia/drug effects , Drug Combinations , Drug Resistance, Fungal , Drug Synergism , Fluconazole/pharmacology , Itraconazole/pharmacology , Miconazole/pharmacology , Microbial Sensitivity Tests
3.
Article in English | MEDLINE | ID: mdl-30373795

ABSTRACT

We evaluated the efficacy of azithromycin (50 mg/kg, every 12 h [q12h] orally) and miltefosine (25 mg/kg, q24h orally) treatments in an experimental model of vascular/disseminated pythiosis in immunosuppressed mice. Azithromycin was the only treatment able to reduce mortality. The histopathological findings showed acute vascular inflammation, pathogen dissemination, necrotizing myositis, neuritis, and arteritis. The results suggest that azithromycin, but not miltefosine, may have clinical relevance in the treatment of vascular/disseminated pythiosis.


Subject(s)
Antiprotozoal Agents/therapeutic use , Azithromycin/therapeutic use , Phosphorylcholine/analogs & derivatives , Pythiosis/drug therapy , Pythium/drug effects , Animals , Immunocompromised Host/immunology , Mice , Phosphorylcholine/therapeutic use , Pythiosis/parasitology
4.
J Immunol Methods ; 449: 56-61, 2017 10.
Article in English | MEDLINE | ID: mdl-28697990

ABSTRACT

Trypanosoma cruzi is a flagellated protozoan belonging to the Trypanosomatidae family, the etiologic agent of Chagas disease. Currently, there is neither a licensed vaccine nor effective treatment, characterizing an unmet clinical need. The IgY refers to the egg yolk immunoglobulin (Y=yolk) and its production and use are subjects of many studies due to the diversity of its diagnostic and therapeutic applications. Several researchers have shown that the use of specific IgY may prevent and/or control infectious and parasitic diseases. Based on these evidences, the aim of this study was to immunize chickens with trypomastigotes of T. cruzi in order to produce highly effective and pure antibodies (IgY), as well as extract, characterize, quantify, and verify cytotoxic effects of IgY anti-T. cruzi. After the induction of IgY production by chickens, the eggs were collected and the IgY was extracted by method of precipitation of polyethylene glycol 6000. The IgY anti-T. cruzi characterization was performed using polyacrylamide gel electrophoresis (SDS-PAGE), western-blot and enzyme-linked immunosorbent assay (ELISA). Moreover, the cytotoxic or proliferative effects of IgY anti-T. cruzi was verified by MTT assay. The concentration of IgY in yolk was 8.41±1.47mg/mL. The characterization of IgY reveled bands of stained peptides with molecular weight between 75 and 50kDa and 37 and 25kDa. In the ELISA test was observed that there was antigen-antibody reaction throughout the sample period. The concentrations of 1, 5 and 10mg/mL of IgY anti-T. cruzi presented no cytotoxic of proliferative effects in mononuclear and VERO cells in vitro. The results indicated that T. cruzi is able to generate a high production of specific immunoglobulins in chickens, it did not cause damage to the cell membrane and no proliferative effect.


Subject(s)
Antibodies, Protozoan/immunology , Antibodies, Protozoan/isolation & purification , Chickens/immunology , Immunoglobulins/immunology , Immunoglobulins/isolation & purification , Trypanosoma cruzi/immunology , Animals , Antibodies, Protozoan/biosynthesis , Blotting, Western , Chlorocebus aethiops , Cytotoxicity Tests, Immunologic , Egg Yolk/chemistry , Egg Yolk/immunology , Electrophoresis, Polyacrylamide Gel , Enzyme-Linked Immunosorbent Assay , Immunization , Immunoglobulins/biosynthesis , Vero Cells
5.
Carbohydr Polym ; 157: 719-727, 2017 Feb 10.
Article in English | MEDLINE | ID: mdl-27987983

ABSTRACT

Pythiosis is a life-threatening infectious disease caused by the pathogenic oomycete Pythium insidiosum. This study is the first to evaluate the P. insidiosum glucan content and its biological activities. The enzymatic quantification of the glucans in P. insidiosum mycelia showed that the ß-glucan content was 18.99%±3.59. The cell wall polysaccharide extract consisted of ∼81.7% carbohydrates (exclusively glucose) and ∼18.3% residual amino acids and peptides. The results from monosaccharide composition, methylation and 1D/2D NMR spectroscopy analyses indicated the presence of a highly branched (1,3)(1,6)-ß-d-glucan, with (1,6)-ß-d-glucopyranosil side-branching unit on average every 1-2 repeat units. In vitro, the ß-d-glucan extract could significantly promote spleen lymphocyte proliferation in human, equine and mouse cell cultures. BALB/c mice that were subcutaneously pre-immunized with three doses of 0.5, 2.5 and 5.0mg of ß-glucan/mouse, showed a significant increase in IL-2, IL-6, IL-10, TNF-α and IL-17A production compared to non-immunized mice. These results suggested that ß-d-glucan extract induces significant and specific Th17 cellular immune response and provided the theoretical basis for further experiments.


Subject(s)
Glucans/chemistry , Pythium/chemistry , Animals , Cells, Cultured , Cytokines/metabolism , Horses , Humans , Immunity, Cellular , Mice , Mice, Inbred BALB C , Monosaccharides , Polysaccharides , Spleen/cytology , Th17 Cells/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...